Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · see citing works

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955 · see citing works

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338 · see citing works

COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER

Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730 · see citing works

Optimal two-stage designs for phase II clinical trials.

Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636 · see citing works

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · see citing works

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871 · see citing works

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial

Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517 · see citing works

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377 · see citing works

Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome

Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815 · see citing works

Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G. V., Rosell, R., Miller, V. A., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,712 · see citing works

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V. A., Manegold, C., Scagliotti, G. V., Rosell, R., Oliff, I. A., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,703 · see citing works

Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer

Cappuzzo, F., Hirsch, F. R., Rossi, E., Bartolini, S., Ceresoli, G. L., Bemis, L., Haney, J., Witta, S. E., Danenberg, K. D., Domenichini, I., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji112 · Cited by 1,538 · see citing works

Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2818 · Cited by 1,220 · see citing works

Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence

Mitsudomi, T., Kosaka, T., Endoh, H., Horio, Y., Hida, T., Mori, S., Hatooka, S., Shinoda, M., Takahashi, T., & Yatabe, Y. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.992 · Cited by 938 · see citing works

Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer

Scagliotti, G. V., de Marinis, F., Rinaldi, M., Crinò, L., Gridelli, C., Ricci, S., Matano, E., Boni, C., Marangolo, M., Failla, G., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.068 · Cited by 889 · see citing works

Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

Han, S., Kim, T., Hwang, P. G., Jeong, S., Kim, J., Choi, I. S., Oh, D., Kim, J. H., Kim, D., Chung, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.388 · Cited by 757 · see citing works

Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer

Miller, V. A., Kris, M. G., Shah, N., Patel, J. D., Azzoli, C. G., Gomez, J. E., Krug, L. M., Pao, W. J., Rizvi, N. A., Pizzo, B., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.158 · Cited by 729 · see citing works

Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer

Takano, T., Ohe, Y., Sakamoto, H., Tsuta, K., Matsuno, Y., Tateishi, U., Yamamoto, S., Nokihara, H., Yamamoto, N., Sekine, I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.0793 · Cited by 691 · see citing works

Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials

Bell, D. W., Lynch, T. J., Haserlat, S. M., Harris, P. L., Okimoto, R. A., Brannigan, B. W., Sgroi, D. C., Muir, B., Riemenschneider, M. J., Iacona, R. B., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7078 · Cited by 598 · see citing works

Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study

Hirsch, F. R., Varella‐Garcia, M., McCoy, J., West, H., Xavier, A. C., Gumerlock, P. H., Bunn, P. A., Franklin, W. A., Crowley, J. J., & Gandara, D. R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.2823 · Cited by 570 · see citing works

High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan

Huang, S.-F. K., Liu, H.-P., Li, L.-H., Ku, Y.-C., Fu, Y.-N., Tsai, H., Chen, Y.-T., Lin, Y., Chang, W.-C., Kuo, H.-P., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1245 · Cited by 545 · see citing works

Genetic Heterogeneity of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Cell Lines Revealed by a Rapid and Sensitive Detection System, the Peptide Nucleic Acid-Locked Nucleic Acid PCR Clamp

Nagai, Y., Miyazawa, H., Huqun, Tanaka, T., Udagawa, K., Kato, M., Fukuyama, S., Yokote, A., Kobayashi, K., Kanazawa, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0331 · Cited by 503 · see citing works

The Relationship between Epidermal Growth Factor Receptor Mutations and Clinicopathologic Features in Non–Small Cell Lung Cancers

Tokumo, M., Toyooka, S., Kiura, K., Shigematsu, H., Tomii, K., Aoe, M., Ichimura, K., Tsuda, T., Yano, M., Tsukuda, K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1167.11.3 · Cited by 489 · see citing works

Severe acute interstitial pneumonia and gefitinib

Inoue, A., Saijo, Y., Maemondo, M., Gomi, K., Tokue, Y., Kimura, Y., Ebina, M., Kikuchi, T., Moriya, T., & Nukiwa, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12190-3 · Cited by 449 · see citing works

Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer☆☆☆☆Abstracted from: Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 2004;22:785–94.

Evans, W. K. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.08.002 · Cited by 405 · see citing works

Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology

Janne, P. A., Engelman, J. A., & Johnson, B. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.985 · Cited by 405 · see citing works

Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer

Chou, T., Chiu, C., Li, L., Hsiao, C.-Y., Tzen, C., Chang, K.-T., Chen, Y., Perng, R.-P., Tsai, S., & Tsai, C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1981 · Cited by 315 · see citing works

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients

Cortés-Funes, H., Gómez, C. G., Rosell, R., Valero, P. M., Girón, C. G., Velasco, A., Izquierdo, Á., Díz, P., Camps, C., Castellanos, D., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi221 · Cited by 229 · see citing works

Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib

Takano, T., Ohe, Y., Kusumoto, M., et al. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.01.010 · Cited by 182 · see citing works

Predictors of the Response to Gefitinib in Refractory Non–Small Cell Lung Cancer

Kim, K., Jeong, J.-Y., Kim, Y., Na, K.-J., Kim, Y., Ahn, S., Baek, S.-M., Park, C.-S., Park, C.-M., Kim, Y., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2081 · Cited by 168 · see citing works

First-Line Single Agent Treatment With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study

Niho, S., Kubota, K., Goto, K., Yoh, K., Ohmatsu, H., Kakinuma, R., Saijo, N., & Nishiwaki, Y. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5825 · Cited by 159 · see citing works

Clinicopathologic Significance of the Mutations of theEpidermal Growth Factor ReceptorGene in Patients with Non–Small Cell Lung Cancer

Tomizawa, Y., Iijima, H., Sunaga, N., Sato, K., Takise, A., Otani, Y., Tanaka, S., Suga, T., Saito, R., Ishizuka, T., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0441 · Cited by 130 · see citing works

Gefitinib-Sensitive Mutations of the Epidermal Growth Factor Receptor Tyrosine Kinase Domain in Chinese Patients with Non–Small Cell Lung Cancer

Mu, X. L., Li, L. Y., Zhang, X. T., Wang, M. Z., Feng, R. E., Cui, Q. C., Zhou, H., & Guo, B. Q. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2506 · Cited by 118 · see citing works

The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer

Zhang, X.-T., Li, L.-Y., Mu, X. L., Cui, Q.-C., Chang, X.-Y., Song, W., Wang, S., Wang, M., Zhong, W., & Zhang, L. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi340 · Cited by 96 · see citing works

PD-160 The relationship between epidermal growth factor receptor (EGFR) mutations and clinicopathologic features in non-small cell lung cancers

Tukumo, M., Toyooka, S., Kiura, K., Shigematsu, H., Asano, H., Aoe, M., Tanimoto, M., Date, H., Gazdar, A. F., & Shimizu, N. (2005) · Lung Cancer · doi:10.1016/s0169-5002(05)80493-3 · Cited by 32 · see citing works

A phase II study of gefitinib as a dirst-line therapy of advanced or metastatic adenocarcinoma of the lung in lifetime non-smokers

Lee, D. H., Han, J. Y., Lee, H. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.7072 · Cited by 16 · see citing works

Upregulation of HER-2/neu is independent of the menopausal status of primary breast cancer patients: Plasma results from a prospectively randomized trial comparing dose-intense chemotherapy with G-CSF support to 3-weekly chemotherapy for adjuvant therapy of nodal-positive (1–3 LN) breast cancer (German Adjuvant Study Group ASG)

Lüftner, D., Schildhauer, S., Eggemann, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.638 · Cited by 4 · see citing works

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · see citing works

Epidermal growth factor receptor mutations in lung cancer

Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170 · see citing works

Detection of Mutations in <i>EGFR</i> in Circulating Lung-Cancer Cells

Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617 · see citing works

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318290868f · Cited by 1,280 · see citing works

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC

Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059 · see citing works

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5622 · Cited by 915 · see citing works

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic <i>EGFR</i> Mutations

Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Jänne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8494 · Cited by 820 · see citing works

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

Crystal, A. S., Shaw, A. T., Sequist, L. V., Friboulet, L., Niederst, M. J., Lockerman, E. L., Frias, R. L., Gainor, J. F., Amzallag, A., Greninger, P., et al. (2014) · Science · doi:10.1126/science.1254721 · Cited by 708 · see citing works

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <i>EGFR</i> and <i>ERBB2</i> Mutations that Are Resistant to Gefitinib

Engelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1885 · Cited by 730 · see citing works

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.97 · Cited by 683 · see citing works

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations

Yano, S., Wang, W., Li, Q., Matsumoto, K., Sakurama, H., Nakamura, T., Ogino, H., Kakiuchi, S., Hanibuchi, M., Nishioka, Y., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1643 · Cited by 643 · see citing works

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

Mitsudomi, T., & Yatabe, Y. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00607.x · Cited by 606 · see citing works

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

Inoue, A., Kobayashi, K., Usui, K., Maemondo, M., Okinaga, S., Mikami, I., Ando, M., Yamazaki, K., Saijo, Y., Gemma, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7658 · Cited by 505 · see citing works

Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway

Nguyen, K.-S. H., Kobayashi, S., & Costa, D. B. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.039 · Cited by 437 · see citing works

Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response

Wu, J.-Y., Wu, S.-G., Yang, C.-H., Gow, C.-H., Chang, Y.-L., Yu, C.-J., Shih, J.-Y., & Yang, P.-C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5123 · Cited by 319 · see citing works

Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Wang, W., Li, Q., Yamada, T., Matsumoto, K., Matsumoto, I., Oda, M., Watanabe, G., Kayano, Y., Nishioka, Y., Sone, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1001 · Cited by 297 · see citing works

Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis

Zhang, Y., Sheng, J., Kang, S., Fang, W., Yan, Y., Hu, Z., Hong, S., Wu, X., Qin, T., Liang, W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107161 · Cited by 175 · see citing works

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives

Russo, A., Franchina, T., Rita Ricciardi, G. R., Picone, A., Ferraro, G., Zanghì, M., Toscano, G., Giordano, A., & Adamo, V. (2015) · Oncotarget · doi:10.18632/oncotarget.4254 · Cited by 173 · see citing works

Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy

Kancha, R. K., von Bubnoff, N., Peschel, C., & Duyster, J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1757 · Cited by 168 · see citing works

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers

Costa, D. B., Kobayashi, S., Tenen, D. G., & Huberman, M. S. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.05.017 · Cited by 160 · see citing works

New therapies for dedifferentiated papillary thyroid cancer

Fallahi, P., Mazzi, V., Vita, R., Ferrari, S., Materazzi, G., Galleri, D., Benvenga, S., Miccoli, P., & Antonelli, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16036153 · Cited by 58 · see citing works

Coexistence of p16/CDKN2A homozygous deletions and activating EGFR mutations in lung adenocarcinoma patients signifies a poor response to EGFR-TKIs

Jiang, J., Gu, Y., Liu, J., Wu, R., Fu, L., Zhao, J., & Guan, Y. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.10.015 · Cited by 47 · see citing works

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non–Small-cell Lung Cancer

Lin, Y.-T., Liu, Y.-N., Wu, S.-G., Yang, J. C.-H., & Shih, J.-Y. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.12.014 · Cited by 43 · see citing works

Clinical usefulness of gefitinib for non-small-cell lung cancer with a double epidermal growth factor receptor mutation

OIKAWA, T., OHIRA, T., OTANI, K., HAGIWARA, M., KONAKA, C., & IKEDA, N. (2015) · Molecular and Clinical Oncology · doi:10.3892/mco.2014.455 · Cited by 9 · see citing works

[Limitation of apoptosis induced by gefitinib in a long-surviving postoperative recurrent lung cancer case].

Kitamura, Y., Sakakura, N., Uchida, T., et al. (2011) · PubMed · Cited by 1 · see citing works

Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy

Endo, K., Sasaki, H., Yano, M., Kobayashi, Y., Yukiue, H., Haneda, H., Suzuki, E., Kawano, O., & Fujii, Y. (2006) · Oncology Reports · doi:10.3892/or.16.3.533 · Cited by 37 · see citing works

Predictive factors for epidermal growth factor receptor inhibitors—The bull's-eye hits the arrow

Dancey, J. E. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00122-9 · Cited by 73 · see citing works

Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

Jackman, D. M., Yeap, B. Y., Sequist, L. V., Lindeman, N., Holmes, A. J., Joshi, V. A., Bell, D. W., Huberman, M. S., Halmos, B., Rabin, M. S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0462 · Cited by 584 · see citing works

Efficacy of Gefitinib for Elderly Patients with Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Gene Mutations: A Retrospective Analysis

Uruga, H., Kishi, K., Fujii, T., Beika, Y., Enomoto, T., Takaya, H., Miyamoto, A., Morokawa, N., Kurosaki, A., & Yoshimura, K. (2010) · Internal Medicine · doi:10.2169/internalmedicine.49.2531 · Cited by 34 · see citing works